Australia markets closed

Kuros Biosciences AG (CSBTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.55000.0000 (0.00%)
At close: 08:33AM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.5500
Open2.5500
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.5500 - 2.5500
52-week range2.0000 - 3.1000
Volume50
Avg. volume193
Market cap83.625M
Beta (5Y monthly)1.02
PE ratio (TTM)N/A
EPS (TTM)-0.1920
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales

    Ad hoc announcement pursuant to Article 53 of the SIX listing rulesMagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020Kuros expanding MagnetOs range to increase perioperative solutions for surgeons SCHLIEREN (ZURICH), Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update on its commercial activities. Direct sales of MagnetOs in the U.S. continued to accelerate in Q3 202

  • GlobeNewswire

    Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting

    New products expand perioperative solutions for surgeonsData to be presented on new formulation of MagnetOs that includes a collagen carrier SCHLIEREN (ZURICH), Switzerland, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will showcase new products in the MagnetOs range at the 36th Annual Meeting of the North American Spine Society (NASS), being held in Boston from September 29 to Octobe

  • GlobeNewswire

    Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

    Ad hoc announcement pursuant to Article 53 of the SIX listing rulesSCHLIEREN (ZURICH), Switzerland, July 15, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: XOMA) under which XOMA has purchased a proportion of the potential future pre-commercial milestone payments and all the potential royalties due under the existing